Tubulis and the US pharmaceutical company Bristol Myers Squibb (BMS) have announced a strategic license agreement to develop the next generation of ultra-stable antibody-drug conjugates (ADCs) for the treatment of solid tumors.
Under the terms of the agreement, Tubulis will receive an upfront payment of $22.75 million, plus milestone-based payments and royalties that have a combined potential value of over $1 billion!
This partnership combines Tubulis’ unique approach for the development of ADCs with BMS’ extensive expertise in oncology and clinical development. As part of the collaboration, Tubulis and BMS will develop a set of different ADCs based on Tubulis’ proprietary P5 conjugation technology and Tubutecan payloads that promise unmatched ADC stability and a highly desirable safety and efficacy profile.
Following the antibody target selection by BMS, Tubulis will provide its linker payloads to generate a uniquely matched ADC for each antibody. BMS will assume sole responsibility for development, manufacturing, and commercialization of the resulting ADC candidates.
Big congratulations to the whole Tubulis team for achieving this amazing success!
More information in the press release under the following Link
More about Tubulis
